Siponimod的药物相互作用研究概述

Summary of Siponimod′s Drug Interaction Study

Siponimod作为首个可以延缓活动性继发进展型多发性硬化症患者残疾进展的药物,国内联合用药研究以及用药经验尚少;对此本文通过汇总国外对Siponimod药物相互作用研究的最新进展,包括CYP2C9/CYP3A4诱导剂及抑制剂、疫苗、避孕药、免疫调节或抑制治疗、抗心律失常药物、β-受体阻滞剂,旨在为联合用药提供参考,避免在临床用药中产生不利影响因素。

Siponimod is the first drug to delay the progress of disability in patients with active secondary progressive but lack of the combined using study a f drugs interaction with Siponimod,including CYP2C9/CYP3A4 inducersand inhibitors,vaccines,contraceptives,immunomodulatory or inhibitory treatments,antiarrhythmic drugs,β-blockers,to provide a reference for combined use and avoid adverse factors in clinical use.